| scholarly article | Q13442814 |
| P356 | DOI | 10.1164/RCCM.200302-200OC |
| P698 | PubMed publication ID | 12893646 |
| P2093 | author name string | Lone Agertoft | |
| Soren Pedersen | |||
| P2860 | cites work | A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler | Q73493368 |
| Improved delivery of inhaled steroids to the large and small airways | Q77670980 | ||
| Lung deposition of budesonide from turbuhaler in asthmatic children | Q77758010 | ||
| Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone | Q77759077 | ||
| Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler | Q28365894 | ||
| The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler | Q34345721 | ||
| Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler | Q36053712 | ||
| Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. | Q40768834 | ||
| A comparison of the efficacy and safety of inhaled corticosteroids in asthma | Q41559651 | ||
| Systemic availability and pharmacokinetics of nebulised budesonide in preschool children | Q42134000 | ||
| Lung deposition and protective effect of terbutaline delivered from pressurized metered-dose inhalers and the Turbuhaler in asthmatic individuals | Q43796660 | ||
| Systemic effect comparisons of six inhaled corticosteroid preparations | Q43997159 | ||
| Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: a 6-month, open- label, randomized trial | Q44058560 | ||
| Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone : a cross-over study in healthy volunteers | Q44097329 | ||
| Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant | Q48737414 | ||
| Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma | Q49083717 | ||
| Lung deposition from the Turbuhaler in children with cystic fibrosis | Q57130833 | ||
| Lung Deposition of Inhaled Drugs Increases with Age | Q57638307 | ||
| Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma | Q57638373 | ||
| The inhalation device influences lung deposition and bronchodilating effect of terbutaline | Q71078892 | ||
| Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI | Q72426713 | ||
| Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler | Q73293418 | ||
| Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers | Q73350565 | ||
| Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in patients with mild-to-moderate asthma | Q73350569 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 779-782 | |
| P577 | publication date | 2003-07-31 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children | |
| P478 | volume | 168 |
| Q36478796 | Airway selectivity: an update of pharmacokinetic factors affecting local and systemic disposition of inhaled steroids |
| Q51808165 | Assessment methods of inhaled aerosols: technical aspects and applications. |
| Q39422648 | Effects of Inhaled Corticosteroids on Growth, Bone Metabolism, and Adrenal Function |
| Q50948479 | Effects of inhaled steroids on growth, bone metabolism and adrenal function. |
| Q36647141 | Effects of inhaled steroids on growth, bone metabolism, and adrenal function |
| Q35939339 | How to match the optimal currently available inhaler device to an individual child with asthma or recurrent wheeze |
| Q24194850 | Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth |
| Q38287834 | Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth. |
| Q38390724 | Inhaled corticosteroids: potency, dose equivalence and therapeutic index |
| Q37554371 | Lung effects of inhaled corticosteroids in a rhesus monkey model of childhood asthma |
| Q36316900 | Paediatric pulmonary drug delivery: considerations in asthma treatment |
| Q35626617 | Pediatrics, surfactant, and cystic fibrosis in AJRCCM 2003. |
| Q36102595 | Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction |
| Q51237805 | Safety and tolerability of inhaled budesonide in children in the Steroid Treatment As Regular Therapy in early asthma (START) trial. |
| Q37428235 | The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial |
Search more.